| Assessment Status | Assessment process complete |
| HTA ID | 20037 |
| Drug | Encorafenib |
| Brand | Braftovi® |
| Indication | In combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, who have received prior systemic therapy |
| Assessment Process | |
| Rapid review commissioned | 05/08/2020 |
| Rapid review completed | 28/09/2020 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of encorafenib plus cetuximab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 30/09/2020 |
| Pre-submission consultation with Applicant | 15/03/2021 |
| Full submission received from Applicant | 29/06/2021 |
| Preliminary review sent to Applicant | 17/09/2021 |
| NCPE assessment re-commenced | 05/11/2021 |
| Factual accuracy sent to Applicant | 23/12/2022 |
| NCPE assessment re-commenced | 10/01/2022 |
| NCPE assessment completed | 28/01/2022 |
| NCPE assessment outcome | The NCPE recommends that encorafenib, in combination with cetuximab, not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.